type of report	**Current report**
number	1/2013
company	PHARMENA

Completion of formal assessment of application to Health Canada for granting permission for bioavailability testing of 1-MNA medicinal product

With reference to Company's Strategy 2012-2015 (released in current report no. 16/2012 of 13th April 2012), the Management Board of PHARMENA S.A. informs that on 7th January 2013, a subsidiary company Cortria Corporation (USA) received notification that Health Canada (an authority supervising clinical trials in Canada) has completed the process of formal assessment of application for granting permission to carry out a bioavailability testing of an innovative anti-atherosclerotic medicinal product based on 1-MNA active substance (working name of the product – TRIA-662). Health Canada has not submitted any comments on the application, therefore, the first stage of the application's verification has concluded. The second stage of the application's verification will feature substantive evaluation of existing tests' results and work planned with respect to further bioavailability testing. Currently, the application has been filed for substantive evaluation. Having performed the substantive evaluation, Health Canada will decide on the submitted application.

Bioavailability testing is indispensible for carrying out phase II of clinical trials ("Proof of Concept") of anti-atherosclerotic medicinal product 1-MNA, in order to confirm its efficacy and absence of adverse side effects with increased doses.

Bioavailability testing determines the time and levels of absorption of medicinal substance into the general circulation of human organism after single administration. A bioavailability testing (randomised, double-blind) on a group of 20 patients is planned. It will focus on two testing groups: 1-MNA vs. niacin (active substance used in currently sold anti-atherosclerotic medicines).

Bioavailability testing will be financed from funds obtained from the issue of series C shares.

In its following current reports, the company will inform about the progress of tests on the innovative 1-MNA anti-atherosclerotic medicinal product.

The information is made public due to the fact that the bioavailability testing of 1-MNA anti-atherosclerotic medicinal product is necessary to carry out phase II of clinical trials of that product. Potential revenue after commercialisation of the anti-atherosclerotic medicinal product may prove to be very beneficial for the financial and economic situation of the Issuer.

Legal basis:
Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board